We are live on ! Find out more
B

Bellecapital Portfolio holdings

AUM $625M Turnover 41.45%
1-Year Est. Return 39.69%
This Fund
S&P 500
This Quarter Est. Return
+5.95%
1 Year Est. Return
+39.69%
3 Year Est. Return
+127.77%
5 Year Est. Return
+155.51%
10 Year Est. Return
+530.96%
AUM
$114M
AUM Growth
+$5.96M
Cap. Flow
+$1.42M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.81%
Holding
78
New
3
Increased
13
Reduced
18
Closed
7
Avg Time Held
1.5 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
1.7 years

Top Sells

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$3.22M
2
CSCO icon
Cisco
CSCO
+$2.07M
3
PFE icon
Pfizer
PFE
+$1.03M
4
IWM icon
iShares Russell 2000 ETF
IWM
+$991K
5
MCK icon
McKesson
MCK
+$851K

Sector Composition

Rank Sector Weight
1 Miscellaneous 26.97%
2 Consumer Discretionary 16.41%
3 Healthcare 15.86%
4 Communication Services 14.66%
5 Technology 12.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PFE icon
76
Pfizer
PFE
$168B
– –
-31,771
Closed -$1.03M –
PRSO icon
77
Peraso
PRSO
$5.75M
– –
-113
Closed -$188K –
TM icon
78
Toyota
TM
$226B
– –
-2,140
Closed -$232K –

Similar funds

Bellecapital's Q2 2017 Portfolio in Review

As of Q2 2017, Bellecapital held 78 positions worth $114M, up 5.5% from $108M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellecapital's Q2 2017 filing shows 3 new, 13 increased, 18 reduced and 7 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 73,180 shares worth $5.49M. The largest sale was Procter & Gamble, an estimated $3.22M.

By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Bellecapital's largest Q2 2017 buy was PRA Health Sciences, Inc.: 73,180 shares worth $5.49M.
  • Bellecapital added most to WisdomTree Japan Hedged Equity Fund in Q2 2017, an estimated $2.66M increase.
  • Bellecapital's biggest Q2 2017 reduction was Procter & Gamble, cutting an estimated $3.22M.
  • Bellecapital fully exited Pfizer in Q2 2017, selling an estimated $1.03M.
  • Bellecapital's ten largest holdings make up 49% of its $114M portfolio in Q2 2017.
  • Bellecapital opened 3 new positions and closed 7 in Q2 2017.
  • Bellecapital's portfolio value rose 5.5% quarter-over-quarter to $114M.

Based on Bellecapital's 13F filing for Q2 2017, filed 26 Jul 2017.